Intech Investment Management LLC Sells 3,240 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Intech Investment Management LLC lowered its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 21.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,903 shares of the biopharmaceutical company’s stock after selling 3,240 shares during the period. Intech Investment Management LLC’s holdings in Regeneron Pharmaceuticals were worth $12,513,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in REGN. SteelPeak Wealth LLC raised its holdings in Regeneron Pharmaceuticals by 173.0% during the second quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock worth $1,148,000 after acquiring an additional 692 shares in the last quarter. Atria Investments Inc boosted its holdings in shares of Regeneron Pharmaceuticals by 12.2% in the 1st quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock valued at $8,317,000 after buying an additional 941 shares during the last quarter. Mizuho Securities USA LLC grew its stake in shares of Regeneron Pharmaceuticals by 625.5% in the third quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock valued at $62,382,000 after buying an additional 51,162 shares in the last quarter. Tri Locum Partners LP increased its holdings in Regeneron Pharmaceuticals by 104.5% during the second quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock worth $18,410,000 after buying an additional 8,949 shares during the last quarter. Finally, Tidal Investments LLC raised its position in Regeneron Pharmaceuticals by 16.8% during the first quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock worth $4,774,000 after acquiring an additional 711 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This trade represents a 27.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.3 %

Shares of NASDAQ REGN opened at $745.48 on Friday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $735.95 and a 52 week high of $1,211.20. The stock’s fifty day moving average is $953.38 and its 200 day moving average is $1,028.16. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The stock has a market capitalization of $81.92 billion, a P/E ratio of 18.45, a PEG ratio of 2.81 and a beta of 0.15.

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of analyst reports. BMO Capital Markets decreased their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Cantor Fitzgerald reiterated a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Royal Bank of Canada dropped their price target on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. Finally, Oppenheimer reduced their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1,099.55.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.